Ventracor sees bright future despite losses
This article was originally published in Clinica
Executive Summary
High expenditure on regulatory activities laid a significant dent in Ventracor's coffers, as the Australian developer of the VentrAssist left ventricle assist device recorded net loss of $36.5m for the year 2006/07. As it strives to expand its coverage in key international markets, the company said it spent heavily on guiding its lead technology through regulatory approvals in the US, Europe and Australia, but hopes to become profitable in the near future.
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.